A recent randomized clinical trial found that sumatriptan reduced insulin sensitivity and glucose effectiveness in overweight humans [40], and a cohort study found that valproate was associated with a higher risk of developing type 2 diabetes in adults [41]. The gene discussed is INS; the disease is type 2 diabetes mellitus.